AmyPore

Our team

The inventors

Jacques Fantini & Nouara Yahi

The scientific discoveries underlying the creation of AmyPore are based on the work of two internationally recognized university professors, Nouara Yahi (Aix-Marseille University) and Jacques Fantini (Aix-Marseille University and Institut Universitaire de France), who together have more than 300 publications in renowned scientific journals.

Nouara Yahi and Jacques Fantini own the intellectual property of the patent and AmyPore has an exclusive operating license to develop AmyP53 as an anti-Alzheimer's and Parkinson's drug worldwide.

Pariente 2
Pr. JEREMIE PARIENTE (M.D. Ph.D.)
Expert neurologist
Professor at Toulouse University Hospital, Jérémie Pariente (M.D., Ph.D.) is head of the service dedicated to cognitive disorders and abnormal movements within the Department of Neurology. Jérémie Pariente has been very involved in the Clinical Investigations Center of the Toulouse University Hospital for many years and has conducted several academic and industrial studies on Alzheimer's disease and related pathologies. Jérémie Pariente is a board member of the French Society of Neurology. He advises AmyPore on setting up clinical trials as part of the development of the AmyP53 program.
driss_fantini
Driss Fantini
President
A Master 2 Grande Ecole Program graduate from Kedge Business School and also from the University of Aix-Marseille entrepreneurship Pépite-PACA, Driss Fantini created the AmyPore Company in 2018, and was therefore responsible for the H2020 SME Phase 1 AmInnovation program.
henri-chahinian
Dr. Henri Chahinian (Ph.D.)
Chairman of the Ethics and Scientific Committee.
Assistant Professor at the University of Aix-Marseille, Dr. Henri Chahinian is an internationally recognized specialist in the biochemistry of lipids and proteins of biological membranes. He has 40 years of experience in basic and applied research.
coralie-di-scala
Dr. Coralie Di Scala (Ph.D.)
Member of the Scientific and Ethics Committee.
Dr. Di Scala obtained his doctoral thesis in 2014 on amyloid pores. She has internationally recognized skills in molecular neuroscience. She is currently leading a neuroscience research team in Helsinki, Finland.
jacques-fantini
Jacques Fantini (Ph.D.)
Member of the ethics and scientific committee
Professor at the University of Aix-Marseille, member of the Institut Universitaire de France, Jacques Fantini is the author of more than 200 scientific publications (including 4 PNAS articles communicated by two Nobel Prizes and two Lasker Prizes). A globally recognized specialist in molecular modeling, he has developed new concepts of artificial intelligence applied to membrane systems in the context of molecular neurosciences and infectious diseases. He is the co-inventor of the patented AmyP53 molecule for which he holds, with Pr. Nouara Yahi, the intellectual property.
nouara-yahi
Nouara Yahi (Ph.D.)
Member of the ethics and scientific committee
Professor at the University of Aix-Marseille, Nouara Yahi is the author of more than 100 scientific publications (including 1 Nature and 2 PNAS communicated by a Nobel Prize and a Lasker Prize). Her work on the mechanisms of HIV infection is directly behind the discovery of the common mechanisms of amyloid pore formation and the role of membrane lipids (gangliosides and cholesterol) in this process. Prof. Nouara Yahi is co-inventor of the patented AmyP53 molecule, of which she, along with Prof. Jacques Fantini, holds the intellectual property.
mohan-sidi-said
Mohand Sidi Saïd
Strategic advisor
Mohand Sidi Saïd is a former Vice-President of Pfizer Inc,. He is the President of an Endowment Fund, an author, and a lecturer, among others at Aix PO and ESSEC in Paris. He is a fervent defender of access to innovative care for the most disadvantaged in our societies. Mohand has authored numerous articles on health models, and he has published "The Spirit and the Molecule" in 2012, "Help, Our Health is in Danger", in 2016, "From Djurdjura to Manhattan", in 2020. Mohand Sidi Saïd is a passionate follower of the knowledge economy, AI and has a unique understanding of the life sciences industry. He joined the Amypore team in 2020 to participate in the development of the AmyP53 solution and contribute with insights and his network.
Screen Shot 2022-01-11 at 7.18.15 PM
Assia Mouri
Project Leader
Graduated from a Master 2 degree in "Cell Biology, Physiology, Pathologies" with a neurosciences mention (Paris Descartes) and a Master of Business and Administration - "Biotechnologies and Management of Health Industries" (Ionis STM, Paris)Assia Mouri began her research career at the prestigious Rockefeller University of New York within the neuroscience laboratory of Dr. Greengard, who has been awarded of the Nobel Prize in Medicine and Physiology in 2000. The world-renowned laboratory is a pioneer in the fight against Alzheimer's and Parkinson's diseases. After an experience in one of the Top 5 pharmaceutical industries worldwide, she has been supporting AmyPore in its growth and operational development since the end of 2021